White matter as a monitoring biomarker for neurodevelopmental disorder intervention studies
Abstract Background Early intervention is a valuable tool to support the development of toddlers with neurodevelopmental disorders. With recent research advances in early identification that allow for pre-symptomatic detection of autism in infancy, scientists are looking forward to intervention duri...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-12-01
|
| Series: | Journal of Neurodevelopmental Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s11689-019-9295-8 |
| _version_ | 1818600950915399680 |
|---|---|
| author | Meghan R. Swanson Heather C. Hazlett |
| author_facet | Meghan R. Swanson Heather C. Hazlett |
| author_sort | Meghan R. Swanson |
| collection | DOAJ |
| description | Abstract Background Early intervention is a valuable tool to support the development of toddlers with neurodevelopmental disorders. With recent research advances in early identification that allow for pre-symptomatic detection of autism in infancy, scientists are looking forward to intervention during infancy. These advances may be supported by the identification of biologically based treatment and outcome measures that are sensitive and dimensional. Main body of abstract The purpose of this review is to evaluate white matter neurodevelopment as a monitoring biomarker for early treatment of neurodevelopmental disorders. Fragile X syndrome (FXS) and autism spectrum disorder (ASD) as used as exemplars. White matter has unique neurobiology, including a prolonged period of dynamic development. This developmental pattern may make white matter especially responsive to treatment. White matter develops aberrantly in children with ASD and FXS. Histologic studies in rodents have provided targets for FXS pharmacological intervention. However, pharmaceutical clinical trials in humans failed to garner positive clinical results. In this article, we argue that the use of neurobiological monitoring biomarkers may overcome some of these limitations, as they are objective, not susceptible to placebo effects, and are dimensional in nature. Short conclusion As the field moves towards earlier detection and early intervention for neurodevelopmental disorders, we encourage scientists to consider the advantages of using neurobiological features as monitoring biomarkers. |
| first_indexed | 2024-12-16T12:43:38Z |
| format | Article |
| id | doaj.art-a202d2c5a84f4f95adfd5e7c6ff7e553 |
| institution | Directory Open Access Journal |
| issn | 1866-1947 1866-1955 |
| language | English |
| last_indexed | 2024-12-16T12:43:38Z |
| publishDate | 2019-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Neurodevelopmental Disorders |
| spelling | doaj.art-a202d2c5a84f4f95adfd5e7c6ff7e5532022-12-21T22:31:21ZengBMCJournal of Neurodevelopmental Disorders1866-19471866-19552019-12-0111111110.1186/s11689-019-9295-8White matter as a monitoring biomarker for neurodevelopmental disorder intervention studiesMeghan R. Swanson0Heather C. Hazlett1School of Behavioral and Brain Sciences, University of Texas at DallasCarolina Institute for Developmental Disabilities, Department of Psychiatry, University of North Carolina at Chapel HillAbstract Background Early intervention is a valuable tool to support the development of toddlers with neurodevelopmental disorders. With recent research advances in early identification that allow for pre-symptomatic detection of autism in infancy, scientists are looking forward to intervention during infancy. These advances may be supported by the identification of biologically based treatment and outcome measures that are sensitive and dimensional. Main body of abstract The purpose of this review is to evaluate white matter neurodevelopment as a monitoring biomarker for early treatment of neurodevelopmental disorders. Fragile X syndrome (FXS) and autism spectrum disorder (ASD) as used as exemplars. White matter has unique neurobiology, including a prolonged period of dynamic development. This developmental pattern may make white matter especially responsive to treatment. White matter develops aberrantly in children with ASD and FXS. Histologic studies in rodents have provided targets for FXS pharmacological intervention. However, pharmaceutical clinical trials in humans failed to garner positive clinical results. In this article, we argue that the use of neurobiological monitoring biomarkers may overcome some of these limitations, as they are objective, not susceptible to placebo effects, and are dimensional in nature. Short conclusion As the field moves towards earlier detection and early intervention for neurodevelopmental disorders, we encourage scientists to consider the advantages of using neurobiological features as monitoring biomarkers.https://doi.org/10.1186/s11689-019-9295-8Autism spectrum disorderFragile X syndromeBrainWhite matterMyelinNeurodevelopment |
| spellingShingle | Meghan R. Swanson Heather C. Hazlett White matter as a monitoring biomarker for neurodevelopmental disorder intervention studies Journal of Neurodevelopmental Disorders Autism spectrum disorder Fragile X syndrome Brain White matter Myelin Neurodevelopment |
| title | White matter as a monitoring biomarker for neurodevelopmental disorder intervention studies |
| title_full | White matter as a monitoring biomarker for neurodevelopmental disorder intervention studies |
| title_fullStr | White matter as a monitoring biomarker for neurodevelopmental disorder intervention studies |
| title_full_unstemmed | White matter as a monitoring biomarker for neurodevelopmental disorder intervention studies |
| title_short | White matter as a monitoring biomarker for neurodevelopmental disorder intervention studies |
| title_sort | white matter as a monitoring biomarker for neurodevelopmental disorder intervention studies |
| topic | Autism spectrum disorder Fragile X syndrome Brain White matter Myelin Neurodevelopment |
| url | https://doi.org/10.1186/s11689-019-9295-8 |
| work_keys_str_mv | AT meghanrswanson whitematterasamonitoringbiomarkerforneurodevelopmentaldisorderinterventionstudies AT heatherchazlett whitematterasamonitoringbiomarkerforneurodevelopmentaldisorderinterventionstudies |